Display options
Cite
Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther. 2016;4(1):17-33doi: 10.1007/s40487-015-0015-6.
Adjiri, A. (2016). Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncology and therapy, 4(1), 17-33. https://doi.org/10.1007/s40487-015-0015-6
Adjiri, Adouda. "Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer." Oncology and therapy vol. 4,1 (2016): 17-33. doi: https://doi.org/10.1007/s40487-015-0015-6
Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther. 2016;4(1):17-33. doi: 10.1007/s40487-015-0015-6. Epub 2016 Jan 20. PMID: 28261638; PMCID: PMC5315067.
Copy Download .nbib Format: NLM
Share it on

Oncol Ther. 2016;4(1):17-33. doi: 10.1007/s40487-015-0015-6. Epub 2016 Jan 20.

Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer.

Oncology and therapy

Adouda Adjiri

Affiliations

  1. Physics Department, Faculty of Sciences, Sétif-1 University, 19000 Sétif, Algeria.

PMID: 28261638 PMCID: PMC5315067 DOI: 10.1007/s40487-015-0015-6

Abstract

Cancer cells continue to challenge scientists and oncologists due to the phenomenon of resistance. Moreover, recurrence, as seen in many treated patients, shows that currently-used anti-cancer drugs are unable to prevent the development of new cancer cells harboring new mutations. The purpose of this paper is to try to answer some of the questions regarding why cancer arises and why evolution would naturally lead to the development of cancer. Providing answers to these questions may shed new light on cancer development and potential causes of cancer. This work demonstrates that (1) cancer hallmarks are a series of events that can be organized in three consecutive stages; (2) cancer may develop when cells seek immortality; (3) heterogeneity in tumors may be explained by cancer cells not following universal laws for division; (4) evolution may not have selected for cancer; (5) currently-used anti-cancer drugs, with telomerase and poly adenosine diphosphate ribose polymerase inhibition given as examples, show that we may not be on the right track, as these drugs are probably targeting molecular symptoms of tumors but not their cause; and (6) after an attempt to define the cause of cancer, the potentials of immunotherapy are discussed. Future anti-cancer drugs should be able to shrink the original tumor(s) and most importantly prevent the rise of new cancer cells in treated patients. In order to achieve this goal, new drugs must target the cause of cancer. Therefore, future research must focus on identifying potential causes of cancer common to all types of cancers. Finally, while immunotherapy holds great prospects for future cancer cure and prevention, global action is needed to reduce harmful substances known to contribute to the development of cancer in the environment.

Keywords: Apoptosis; Cancer hallmarks; Cancer-cell resistance; Cause of cancer; Evolution; Immortality; Senescence

References

  1. Nat Med. 2013 Nov;19(11):1381-8 - PubMed
  2. Nature. 2010 Mar 18;464(7287):374-9 - PubMed
  3. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166-70 - PubMed
  4. Int J Radiat Biol. 2013 Sep;89(9):692-7 - PubMed
  5. Cell. 1997 Mar 7;88(5):593-602 - PubMed
  6. Cell. 2005 Feb 25;120(4):513-22 - PubMed
  7. Nature. 2005 Apr 14;434(7035):864-70 - PubMed
  8. Expert Rev Anticancer Ther. 2007 Oct;7(10):1405-21 - PubMed
  9. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23 - PubMed
  10. Int J Cancer. 1996 Jun 11;66(6):732-7 - PubMed
  11. Cell. 2012 Feb 17;148(4):651-63 - PubMed
  12. Int Immunol. 2015 Jan;27(1):39-46 - PubMed
  13. Nat Rev Cancer. 2011 Mar;11(3):161-76 - PubMed
  14. J Cell Biol. 2011 Feb 21;192(4):547-56 - PubMed
  15. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  16. IARC Sci Publ. 1982;(39):9-25 - PubMed
  17. Genes Dev. 2012 May 1;26(9):877-90 - PubMed
  18. Cancer Immunol Immunother. 2009 Mar;58(3):317-24 - PubMed
  19. J Clin Oncol. 2011 Dec 20;29(36):4828-36 - PubMed
  20. Nat Rev Cancer. 2005 Jul;5(7):516-25 - PubMed
  21. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9082-6 - PubMed
  22. Br J Cancer. 1972 Aug;26(4):239-57 - PubMed
  23. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  24. Cell. 2015 Jun 18;161(7):1539-52 - PubMed
  25. Trends Cell Biol. 1999 Dec;9(12):M57-60 - PubMed
  26. Semin Cancer Biol. 2011 Dec;21(6):367-76 - PubMed
  27. J Radiat Res. 2011;52(5):545-56 - PubMed
  28. In Vivo. 2000 Jan-Feb;14(1):183-8 - PubMed
  29. Nature. 1991 Apr 18;350(6319):569-73 - PubMed
  30. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  31. Nat Rev Mol Cell Biol. 2002 Oct;3(10):779-87 - PubMed
  32. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  33. Science. 1996 Jul 5;273(5271):63-7 - PubMed
  34. N Engl J Med. 2009 Jul 9;361(2):123-34 - PubMed
  35. Cancer Res. 2009 Oct 15;69(20):7917-25 - PubMed
  36. BMC Cancer. 2011 May 27;11:203 - PubMed
  37. Semin Cancer Biol. 1993 Apr;4(2):129-40 - PubMed
  38. Genes Dev. 1999 Jun 15;13(12):1501-12 - PubMed
  39. Metabolism. 2015 Mar;64(3 Suppl 1):S16-21 - PubMed
  40. Nat Rev Cancer. 2002 Sep;2(9):683-93 - PubMed
  41. Eur J Cancer. 1997 Apr;33(5):767-73 - PubMed
  42. Nat Rev Mol Cell Biol. 2006 Sep;7(9):667-77 - PubMed
  43. Mol Cancer Ther. 2014 Feb;13(2):433-43 - PubMed
  44. Br J Cancer. 1953 Mar;7(1):68-72 - PubMed
  45. Cancer Res. 2014 Mar 15;74(6):1639-44 - PubMed
  46. N Engl J Med. 2013 Jul 11;369(2):134-44 - PubMed
  47. Pharmacotherapy. 2012 Dec;32(12):1095-111 - PubMed
  48. Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40 - PubMed
  49. Science. 1997 Aug 15;277(5328):955-9 - PubMed
  50. Cancer Sci. 2013 May;104(5):525-30 - PubMed
  51. Genes Chromosomes Cancer. 1998 Jun;22(2):157-63 - PubMed
  52. J Natl Cancer Inst. 2011 Aug 17;103(16):1222-6 - PubMed
  53. Eur J Cancer. 1997 Apr;33(5):787-91 - PubMed
  54. J Clin Oncol. 2014 Apr 1;32(10):1020-30 - PubMed
  55. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 - PubMed
  56. Cell. 2007 Jan 26;128(2):295-308 - PubMed
  57. Curr Pharm Biotechnol. 2009 Feb;10(2):166-84 - PubMed
  58. Science. 1995 Sep 1;269(5228):1236-41 - PubMed
  59. Nat Rev Cancer. 2004 Sep;4(9):737-47 - PubMed
  60. Genes Dev. 2010 Nov 15;24(22):2463-79 - PubMed
  61. Carcinogenesis. 2009 Jul;30(7):1073-81 - PubMed
  62. Biochimie. 1999 Jan-Feb;81(1-2):69-75 - PubMed
  63. Clin Cancer Res. 2014 Feb 1;20(3):540-7 - PubMed
  64. Cancer Res. 2001 Mar 15;61(6):2744-50 - PubMed
  65. Strahlenther Onkol. 2007 Jun;183(6):295-300 - PubMed
  66. Cancer Cell. 2013 May 13;23 (5):618-33 - PubMed
  67. Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77 - PubMed
  68. J Exp Med. 2011 Feb 14;208(2):395-407 - PubMed
  69. Nat Genet. 1999 Feb;21(2):220-4 - PubMed
  70. Br J Cancer. 2015 Apr 28;112(9):1421-7 - PubMed
  71. J Exp Clin Cancer Res. 2011 Sep 26;30:87 - PubMed
  72. Oncogene. 2003 May 19;22(20):3063-9 - PubMed
  73. Anticancer Res. 2014 Apr;34(4):1493-505 - PubMed
  74. Oncogene. 2003 Sep 1;22(37):5848-54 - PubMed
  75. Nat Genet. 2004 Jan;36(1):63-8 - PubMed
  76. Cell. 2011 Nov 11;147(4):742-58 - PubMed
  77. Cell. 1990 Dec 21;63(6):1129-36 - PubMed
  78. J Natl Cancer Inst. 2013 Feb 20;105(4):256-65 - PubMed
  79. Nature. 1991 Jul 25;352(6333):345-7 - PubMed
  80. EMBO J. 1995 Sep 1;14(17):4240-8 - PubMed
  81. Nat Med. 2004 Aug;10 (8):789-99 - PubMed
  82. Nature. 2005 Aug 4;436(7051):720-4 - PubMed
  83. Bioessays. 1991 Sep;13(9):455-62 - PubMed
  84. Oncogene. 2014 Sep 18;33(38):4623-31 - PubMed

Publication Types